Key Highlights

  • Net loss was $18.9 million, or $1.76 per basic and diluted share.
  • Pivotal lupus nephritis study start-up activities are underway for prula-cel.
  • An FDA meeting is planned in the fourth quarter of 2026 regarding potential pivotal expansion beyond lupus nephritis.
  • Non-cash charges in the quarter totaled $2.7 million.

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company developing allogeneic Gamma Delta CAR-T cell and in vivo CAR-T therapies, reported third quarter 2026 results. The company recorded a net loss of $18.9 million, or $1.76 per basic and diluted share, for the three months ended September 30, 2026. Management said the growing body of evidence for its lead candidate, prula-cel, supports its conviction in the program's potential to produce lasting remissions in lupus.

Prula-cel Development Plans

Start-up activities for a pivotal lupus nephritis study of prula-cel are underway. The planned single-arm study is expected to enroll a double-digit number of patients, with complete renal response at 12 months as the primary efficacy endpoint. The design indicates that the company intends to use a focused patient group and a defined kidney response measure for its pivotal evidence.

The company plans an FDA meeting in the fourth quarter of 2026 to discuss potential pivotal expansion beyond lupus nephritis. The company also expects a regulatory update and additional 12-month clinical data.

Operating Results and Cost Structure

The net loss of $18.9 million includes non-cash charges of $2.7 million, primarily share-based compensation, Depreciation and non-cash Lease expense. Share-based compensation was $0.8 million in Research and Development expense and $0.7 million in general and administrative expense, which shows how much of the operating cost is non-cash.

Because the company is preparing a pivotal study, its spending is expected to rise as trial activities move from start-up to enrollment. The release frames the current quarter as a period of preparation rather than Revenue generation, which is typical of clinical-stage biotechnology companies.

Sector Context and What to Watch

Cell therapies for autoimmune disease are an active area of development, with several companies pursuing lupus and related indications. Regulatory feedback on the scope of pivotal programs is often a decisive step, which is why the fourth quarter FDA meeting is a key milestone for the company.

Each will indicate whether the pivotal program advances on the planned timeline and how the company's expenses are likely to develop.

Final Takeaways

Adicet Bio reported a quarterly net loss of $18.9 million and is moving its lead candidate toward pivotal study. The fourth quarter FDA meeting will determine the scope of the next step, while the pivotal start-up and additional clinical data will shape the company's timeline. Subsequent updates will indicate progress on those milestones.